inhibition of experimental corneal neovascularization by bevacizumab (avastin) baskent university,...
TRANSCRIPT
![Page 1: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/1.jpg)
Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin)
Baskent University, School of Medicine Department of Ophthalmology, Ankara Turkey
Yonca A. Akova, MDVeysi Öner, MDCem Küçükerdönmez, MD
The authors acknowledge no financial interest in the subject matter of this presentation
![Page 2: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/2.jpg)
Purpose
To evaluate and compare the inhibitory
effects of topical high dose, low-dose
and subconjunctival bevacizumab
(Avastin, Genentech Inc., San
Francisco, Ca, USA) on corneal
vascularization in a rat model
![Page 3: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/3.jpg)
Methods
• Corneas of 20 rats (Sprague-Dawley, male) were chemically cauterized with silver nitrate sticks in order to induce neovascularization
• Animals were divided in four groups
•Group 1: Control group that received only topical artificial tear twice daily
•Grup 2: Subconjunctival injection group that received 0.05 ml (1.25mg) of bevacizumab on day 1, 4 and 7
•Group 3: Low-dose topical bevacizumab (4 mg/ml) group that received twice daily
•Group 4: High-dose topical bevacizumab (12.5 mg/ml) group that received twice daily
![Page 4: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/4.jpg)
Methods
• Digital photographs of the corneas were taken and analyzed using an image analysis software (Pixcavator Image Analyzer, Intelligent Perception,WV, USA)
• On day 10, all animals were sacrificed and the eyes were enucleated
• Corneas were excised and examined histopathologically
![Page 5: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/5.jpg)
Control group
Group 2 Group 3 Group 4
Mean percentage of neovascularized corneal area (%)
63.32
± 13.10
30.22
± 15.73
26.76
± 10.23
25.52
± 12.45
p value < 0.01 < 0.01 < 0.01
Results
![Page 6: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/6.jpg)
Control group Topical high-dose bevacizumab group (12.5 mg/ml)
![Page 7: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/7.jpg)
Control group Topical low-dose bevacizumab group (4 mg/ml)
![Page 8: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/8.jpg)
Subconjunctival bevacizumab group (1.25mg/0,05ml)
Control group
![Page 9: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/9.jpg)
Results• In histological examination of the excised corneas,
treated eyes showed significantly less neovascular areas and number of vessels in group 2,3 and 4 than the control group
• The differences between control group and treatment groups were found to be statistically significant (p < 0.05 for all)
• Bevacizumab is able to inhibit corneal angiogenesis, without any difference of this effect with – Changing the route of administration
(subconjunctival or topical) – Increasing the dosage (4mg/ml or 12.5mg/ml for
topical form)
![Page 10: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/10.jpg)
Control group Topical low-dose bevacizumab group
![Page 11: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/11.jpg)
Discussion
• Both topical and subconjunctival application of bevacizumab reduces experimental corneal vascularization significantly compared to the control group
• Clinical use of bevacizumab may have an additional effect in the treatment for corneal neovascularization
![Page 12: Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara](https://reader036.vdocument.in/reader036/viewer/2022082712/56649f345503460f94c52467/html5/thumbnails/12.jpg)
NAME: Yonca Aydın Akova, M.D.
TITLE: Professor in Ophthalmology
DATE AND PLACE OF BIRTH: October 21, 1960, Turkey
1983: Doctor of Medicine, Istanbul University, School of Medicine
1990: Istanbul University, School of Medicine, Department of Ophthalmology
2000: Professor of Ophthalmology, Baskent University, School of Medicine, Department of Ophthalmology, Ankara, Turkey
2002: Chairperson, Baskent University, School of Medicine, Department of Ophthalmology, Ankara, Turkey
NAME: Cem Küçükerdönmez, M.D.
TITLE: Fellow in Ophthalmology
DATE AND PLACE OF BIRTH: October 9, 1975, Turkey
1999: Doctor of Medicine, Hacettepe University, School of Medicine
2003 : Başkent University, School of Medicine, Department of Ophthalmology
NAME:, Veysi Öner, M.D.TITLE: Resident in OphthalmologyDATE AND PLACE OF BIRTH: March 01, 1979, Turkey2002: Doctor of Medicine, Hacettepe University, School of Medicine2003-2008 : Resident, Başkent University, School of Medicine, Department of Ophthalmology, Ankara, Turkey